Lanco Medical Group facilita el acceso al tratamiento inicial aprobado por la FDA para el carcinoma nasofaríngeo en Centroamérica.
The announcement of TopAlliance Biosciences, a wholly-owned subsidiary of Junshi Biosciences of FDA approval of LOQTORZI™ (toripalimab-tpzi), marks a success in the treatment of nasopharyngeal carcinoma (NPC). This treatment, the first and only FDA approved for this condition, will now be available in Central America thanks to Lanco Medical Group’s robust platform and regional presence, ensuring this vital treatment is no longer needed. TopAlliance Biosciences trusted Lanco Medical Gro...
